Merck Ends Acquisition Talks with Revolution Medicines Over Price: Report

Merck & Co. has terminated negotiations to acquire biotechnology firm Revolution Medicines, according to a report on January 26, 2026. The deal collapsed due to a failure to agree on financial terms. The discussions, which were previously undisclosed, have now ended. Revolution Medicines focuses on developing cancer treatments targeting RAS mutations, a key oncology research area. No specific price figures were disclosed in the report detailing the disagreement.